Rachel M. Burns

Cooley advised Grafana Labs, the company behind ubiquitous, open and composable operational dashboards, on the successful completion of its approximately $270 million primary and secondary transaction.

Cooley advised Motive, a leading automated operations platform for the physical economy, on its $150 million Series F financing round, bringing the company’s valuation to $2.85 billion. Lawyers Rachel Burns and Rachel Proffitt led the Cooley team advising Motive.

Cooley advised Gusto, a San-Francisco based payroll software company, on its agreement to acquire Symmetry, a longtime leader in payroll infrastructure technology. Cooley Partner Laura Medina led the team advising Gusto.

Read more

Cooley advised Vera Therapeutics on its $47.85 million initial public offering of 4,350,000 shares of class A common stock. Vera Therapeutics, whose securities now trade on the Nasdaq Global Market under the symbol VERA, is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Partners Jodie Bourdet and Carlton Fleming led the Cooley team.

Cooley advised Origin, the world’s leading carbon negative materials company, on its agreement to combine with Artius, a publicly traded special purpose acquisition company or SPAC. The combined company, which is expected to have an equity value of approximately $1.8 billion, will be named Origin Materials and remain listed on the Nasdaq under the new ticker symbol “ORGN.” Partners Garth Osterman and Peter Werner led the Cooley team advising Origin.